Nanoemulsions in Cancer Therapeutics

Mj, Nirmala; Nagarajan, R.

doi:10.4172/2157-7439.1000e137

Search citation statements

Order By: Relevance

Paper Sections

Select...

Advantages Of Nanoparticle Encapsulated Drug Delivery System1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the above formulation had showcased lesser lethality in comparison to chemotherapy drug Taxol. 26 Drug intake, its circulations, metabolism, and removal from the body of an anti-HIV or anti-Covid-19 drug can be enhanced by nano-particle encapsulation or conjugation. [27][28] Nanocomposite modifies the physical and chemical properties which modifies the tissue distribution of the HIV affected organs in human body.…”

Section: Advantages Of Nanoparticle Encapsulated Drug Delivery Systemmentioning

confidence: 99%

Recent advancement in nanomaterial-encapsulated drug delivery vehicles for combating cancer, COVID-19, and HIV-like chronic diseases

Paul

Mukherjee²,

Banerjee

2023

Mater. Adv.

View full text Add to dashboard Cite

show abstract

Section: Advantages Of Nanoparticle Encapsulated Drug Delivery Systemmentioning

confidence: 99%

Recent advancement in nanomaterial-encapsulated drug delivery vehicles for combating cancer, COVID-19, and HIV-like chronic diseases

Paul

Mukherjee²,

Banerjee

2023

Mater. Adv.

View full text Add to dashboard Cite

show abstract

Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)

et al. 2022

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is considered one of the un-manageable types of breast cancer, involving devoid of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER 2) receptors. Due to their ability of recurrence and metastasis, the management of TNBC remains a mainstay challenge, despite the advancements in cancer therapies. Conventional chemotherapy remains the only treatment regimen against TNBC and suffers several limitations such as low bioavailability, systemic toxicity, less targetability, and multi-drug resistance. Although various targeted therapies have been introduced to manage the hardship of TNBC, they still experience certain limitations associated with the survival benefits. The current research thus aimed at developing and improving the strategies for effective therapy against TNBC. Such strategies involved the emergence of nanoparticles. Nanoparticles are designated as nanocavalries, loaded with various agents (drugs, genes, etc.) to battle the progression and metastasis of TNBC along with overcoming the limitations experienced by conventional chemotherapy and targeted therapy. This article documents the treatment regimens of TNBC along with their efficacy towards different subtypes of TNBC, and the various nanotechnologies employed to increase the therapeutic outcome of FDA-approved drug regimens.

show abstract

Nanoemulsions in Cancer Therapeutics

Cited by 2 publications

References 6 publications

Recent advancement in nanomaterial-encapsulated drug delivery vehicles for combating cancer, COVID-19, and HIV-like chronic diseases

Recent advancement in nanomaterial-encapsulated drug delivery vehicles for combating cancer, COVID-19, and HIV-like chronic diseases

Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)

Contact Info

Product

Resources

About